IBI 321
Alternative Names: IBI-321Latest Information Update: 09 Mar 2023
At a glance
- Originator Innovent Biologics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 23 Feb 2023 Innovent Biologics completes a Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Recurrent, Second-line therapy or greater) in China (IV) (NCT04911881)
- 17 Feb 2023 Innovent Biologics completes a Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Recurrent, Second-line therapy or greater) in China (IV) (NCT04911894)
- 31 Dec 2021 Innovent Biologics plans a phase Ib trial for Solid tumors (Late-stage disease, Monotherapy or Combination therapy) in China (NCT05172856)